TPI provides its latest research note on N4 Pharma plc (N4P.L).

N4P has released an update on its ongoing work programmes.

Taking advantage of its virtual model and contracted laboratories, the Group has been able to make significant progress, moving its testing schedules forward despite the Pandemic lockdown. Data derived from optimisation work investigating different formulations of Nuvec® is now being analysed in anticipation of incorporation into the optimised strand of the pending in vivo study.

Meanwhile, planning for the unoptimised in vivo study to compare the reactions of Nuvec® loaded with the Coronavirus and another generic plasmid in generating relevant antibodies, has also been finalised and is due to commence shortly.

Taken together with feasibility work into oral applications and the ongoing technology transfer for the manufacture of Nuvec®, the next six months or so is likely to be pivotal for N4P as a deeper understanding of the potential for its unique, non-viral adjuvant delivery system is established and collaboration talks possibly get underway.

Read More

We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to N4 Pharma plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.

The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

Copyright © 2019 Turner Pope Investments (TPI) Limited, all rights reserved.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.